RNA drug maker grew revenue 85% to $1.1B but trades at 70x earnings — classic Lynch fast grower discovered too late.
A classic fast grower achieving profitability after years of losses, but the market has already discovered and priced the story to perfection.
What kind of company is this, and what should we expect?
This framework classifies Alnylam as a textbook fast grower — 65.2% TTM revenue growth with volatile but improving profitability. The extreme operating leverage and high R&D intensity are classic biotech fast grower characteristics that Lynch would recognize as both opportunity and risk.
Can you explain why this company grows in one sentence?
The story is crystal clear: "They make RNA drugs that treat rare diseases." Simple enough for an eleven-year-old. But with only two products generating all revenue, this framework would note the concentration risk alongside the clarity.
Are we paying a fair price for the growth we're getting?
Applying this lens shows a PEG below 1.0, which Lynch would find interesting. However, this framework recognizes the sustainability question — can 85% growth continue? The market's implied 5.16% perpetual growth suggests skepticism.
Are we early, middle, or late in this growth story?
This framework sees middle-to-late innings. The profitability inflection suggests the story isn't over, but 98.7% institutional ownership and peak valuation multiples indicate the market has fully discovered this company. Lynch preferred finding companies before the institutions piled in.
Applying this framework reveals a classic fast grower that Lynch would have loved finding five years ago. The story is simple (RNA drugs for rare diseases), the growth is real (85% YoY), and insiders are buying. But at 70x earnings with 98.7% institutional ownership, the easy money has been made. Is this still a growth story worth owning, or just a growth story worth admiring?
This analysis applies Peter Lynch's published investment framework to publicly available financial data. It is not authored by, endorsed by, or affiliated with Peter Lynch. Educational purposes only. Not financial advice.